News Alexion drug fails in kidney transplant trial Soliris fails when used to treat post-transplant complications.
News Alexion's new CFO promises to put cash to good use After announcing the shock departure of Alexion's chief executive and chief financial officer yesterday, the company's chairman Leonard Bell quickly named David Brennan, ex-AstraZeneca chie
Articles Alexion: aiming to break new ground in ultra-rare therapies Martin Mackay, head of R&D at Alexion, talks to pharmaphorum about the company's research pipeline for severe and ultra-rare diseases.
News Kanuma approval adds to Alexion rare disease roster Alexion has gained FDA approval for Kanuma, its treatment for the rare disease lysosomal acid lipase (LAL) deficiency.
News Rare disease drug Strensiq too expensive, says NICE Alexion's new rare disease treatment Strensiq has been rejected by England's health watchdog NICE in draft guidance.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
